All paxlovid articles
-
BusinessNew Covid-19 antiviral cuts symptoms by 1.5 days
Simnotrelvir already has emergency approval in China
-
BusinessProtective treatment for Covid-19 makes minimal impact
Limited uptake of antibody combination for vulnerable patients, while demand for antivirals seems to be slowing
-
BusinessWhat is the future of Covid-19 pharmaceuticals?
Firms anticipate long-term markets for prevention and treatment
-
OpinionThe shadow of drug resistance
Why do some medicines stop working, and can we avoid it for Covid-19 antivirals?